Behandlung des metastasierten Nebennierenkarzinoms mit Suramin

Research output: Contribution to journalArticlepeer-review


  • B Allolio
  • C Jaursch-Hancke
  • M Reincke
  • U Metzler
  • W Winkelmann

Colleges, School and Institutes


A right adrenocortical carcinoma (weighing 978 g) was removed from a 45-year-old man in April 1986, the tumour bed then being irradiated with 40 Gy. Subsequently discovered multiple lung metastases were treated with cisplatin, etoposide and bleomycin, without improvement. Treatment with mitotane (Lysodren) was also without effect and had to be discontinued because of severe side effects. Treatment with suramin (Germanin) was begun in August 1987. After a loading dose of 10.7 g for six weeks the lung metastases regressed almost completely. But lung metastases were again demonstrated in January 1988 during a low-dose maintenance regimen of suramin. Increased dosage arrested further growth, but achieved no regression of the metastases. The patient died unexpectedly in April 1988 of acute circulatory failure. Suramin administration had been discontinued six weeks earlier because of bronchopneumonia and general deterioration. Thrombocytopenia, coagulation disorders and moderate proteinuria were the side effects of suramin treatment.


Translated title of the contributionTreatment of metastatic adrenal carcinoma with suramin
Original languageGerman
Pages (from-to)381-4
Number of pages4
JournalDeutsche Medizinische Wochenschrift
Issue number10
Publication statusPublished - 10 Mar 1989


  • Adrenal Cortex Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Combined Modality Therapy, Dose-Response Relationship, Drug, Drug Evaluation, Humans, Lung Neoplasms, Male, Middle Aged, Radiotherapy Dosage, Remission Induction, Suramin, Time Factors